New combo shows promise for Tough-to-Treat lung cancer
NCT ID NCT05941897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if the combination can shrink tumors. Researchers will also track how long any response lasts and how quickly it occurs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceralasertib and durvalumab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with only 39 participants and no comparison group, so results may not be conclusive. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 115533, Russia
-
Research Site
Moscow, 125284, Russia
-
Research Site
Moscow, 143423, Russia
-
Research Site
Nizhny Novgorod, 603126, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Saint Petersburg, 198255, Russia